DE602004031405D1 - Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten - Google Patents

Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten

Info

Publication number
DE602004031405D1
DE602004031405D1 DE200460031405 DE602004031405T DE602004031405D1 DE 602004031405 D1 DE602004031405 D1 DE 602004031405D1 DE 200460031405 DE200460031405 DE 200460031405 DE 602004031405 T DE602004031405 T DE 602004031405T DE 602004031405 D1 DE602004031405 D1 DE 602004031405D1
Authority
DE
Germany
Prior art keywords
response
predict
marker
therapy
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200460031405
Other languages
English (en)
Inventor
John Foekens
Nadia Harbeck
Thomas Koenig
Sabine Maier
John Martens
Fabian Model
Inko Nimmrich
Tamas Rujan
Manfred Schmitt
Ralf Lesche
Dimo Dietrich
Volkmar Mueller
Antje Kluth
Ina Schwope
Oliver Hartmann
Heinz Hoefler
Peter Adorjan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenomics AG
Original Assignee
Epigenomics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics AG filed Critical Epigenomics AG
Publication of DE602004031405D1 publication Critical patent/DE602004031405D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE200460031405 2003-12-11 2004-12-13 Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten Active DE602004031405D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP03090432 2003-12-11
EP04090041 2004-02-10
EP04090127 2004-04-01
EP04013328 2004-06-05
EP04090380 2004-09-30
EP04027213 2004-11-16

Publications (1)

Publication Number Publication Date
DE602004031405D1 true DE602004031405D1 (de) 2011-03-31

Family

ID=34637445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200460031405 Active DE602004031405D1 (de) 2003-12-11 2004-12-13 Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten

Country Status (8)

Country Link
US (1) US9017944B2 (de)
EP (1) EP1692316A2 (de)
JP (2) JP2005204651A (de)
AT (1) ATE498693T1 (de)
AU (3) AU2004298537A1 (de)
CA (2) CA2549852A1 (de)
DE (1) DE602004031405D1 (de)
WO (1) WO2005059172A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
ATE437962T1 (de) * 2002-10-01 2009-08-15 Epigenomics Ag Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
ATE498693T1 (de) * 2003-12-11 2011-03-15 Epigenomics Ag Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten
JP2008506407A (ja) * 2004-07-18 2008-03-06 エピゲノミクス アーゲー 乳房細胞増殖性疾患を検出するためのエピジェネティックな方法および核酸
EP2213749A1 (de) 2004-12-02 2010-08-04 Epigenomics AG Verfahren und Nukleinsäuren zur Analyse von mit der Prognose von Störungen der Proliferation von Prostatazellen assoziierter Genexpression
CA2606296C (en) 2005-04-15 2019-05-21 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
WO2006131391A1 (en) * 2005-06-10 2006-12-14 Epigenomics Ag Prognostic assay for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2007003397A2 (en) * 2005-07-01 2007-01-11 Epigenomics Ag Method and nucleic acids for the improved treatment of cancers
WO2007047699A1 (en) * 2005-10-17 2007-04-26 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cancers
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US8068994B2 (en) * 2007-07-27 2011-11-29 Wayne State University Method for analyzing biological networks
CN101861398A (zh) * 2007-09-17 2010-10-13 皇家飞利浦电子股份有限公司 用于乳腺癌紊乱分析的方法
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
CA2759312C (en) * 2009-04-20 2019-12-31 Erasmus University Medical Center Rotterdam Method of diagnosing bladder cancer
EP2450455B1 (de) * 2009-06-30 2016-03-16 Sysmex Corporation Verfahren zur bestimmung der präsenz oder absenz epithelialkrebsbildender zellen in einer biologischen probe sowie kit dafür
WO2011112947A1 (en) * 2010-03-12 2011-09-15 Cenetron Diagnostics Llc Methods and compositions comprising nucleic acid polymerization enhancers
EP2505665A1 (de) * 2011-03-31 2012-10-03 Queen Mary And Westfield College, University Of London Krebsmarker
US10752953B2 (en) 2011-05-12 2020-08-25 The Johns Hopkins University Method of detecting cancer through generalized loss of stability of epigenetic domains, and compositions thereof
SI2729579T1 (en) 2011-07-08 2018-07-31 Epigenomics Ag METHODS AND NUCLEAR ACIDS FOR THE DETERMINATION OF A CERTAIN PERSON PROBLEM
US10316361B2 (en) 2011-07-15 2019-06-11 The John Hopkins University Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence
GB201204785D0 (en) * 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
US20170211035A1 (en) 2016-01-25 2017-07-27 American Sterilizer Company Biological indicators
JPWO2017145739A1 (ja) * 2016-02-24 2018-09-20 富士フイルム株式会社 染色体数定量方法
CN116445593A (zh) 2016-08-10 2023-07-18 格里尔公司 测定一生物样品的一甲基化图谱的方法
EP3652343A1 (de) * 2017-07-13 2020-05-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Digitale tröpfchen-pcr-strategie mit zwei sonden zur spezifischen detektion gewebespezifischer zirkulierender dna-moleküle
US20210087639A1 (en) * 2018-03-26 2021-03-25 Rush University Medical Center Method of Treatment Utilizing a Gene Expression Signature Predicting the Response of HER2-Directed Therapies
CN113226383B (zh) 2018-12-27 2023-08-01 3M创新有限公司 用于灭菌监测的多层测试包
JP2022526415A (ja) * 2019-04-03 2022-05-24 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 血漿中の膵管腺癌の検出
WO2020252721A1 (en) * 2019-06-20 2020-12-24 The Johns Hopkins University Dna methylation markers and their use in differentiation of suspected cancerous lymph node biopsy samples
KR20210026867A (ko) * 2019-09-02 2021-03-10 주식회사 시선바이오머티리얼스 신규한 pna 올리고머, 이의 dna 메틸화 검출용도 및 이를 이용한 dna 메틸화 검출방법
CN115910365B (zh) * 2022-11-16 2024-02-13 华中科技大学同济医学院附属同济医院 Eos-CRSwNP术前难治性评估模型的构建方法及预测系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
SE501439C2 (sv) 1993-06-22 1995-02-13 Pharmacia Lkb Biotech Sätt och anordning för analys av polynukleotidsekvenser
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
EP0889122A3 (de) 1993-11-30 1999-03-03 McGILL UNIVERSITY DNA Methyltransferase Inhibierung
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
DE19754482A1 (de) 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6596488B2 (en) 2000-03-30 2003-07-22 City Of Hope Tumor suppressor gene
AUPR142500A0 (en) * 2000-11-13 2000-12-07 Human Genetic Signatures Pty Ltd A peptide nucleic acid-based assay for the detection of specific nucleic acid sequences
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
DE10228917A1 (de) 2002-06-24 2004-01-22 Epigenomics Ag Vorrichtung zur Handhabung von Flüssigkeiten in einer Mehrzahl von Kanälen
ATE437962T1 (de) 2002-10-01 2009-08-15 Epigenomics Ag Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
ATE498693T1 (de) * 2003-12-11 2011-03-15 Epigenomics Ag Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten
WO2006113671A2 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers

Also Published As

Publication number Publication date
US9017944B2 (en) 2015-04-28
WO2005059172A2 (en) 2005-06-30
JP2005204651A (ja) 2005-08-04
AU2004237861B2 (en) 2010-04-29
AU2004237861A1 (en) 2005-06-30
CA2487578A1 (en) 2005-06-11
US20080254447A1 (en) 2008-10-16
EP1692316A2 (de) 2006-08-23
AU2010201017A1 (en) 2010-04-08
JP2007513621A (ja) 2007-05-31
AU2004298537A1 (en) 2005-06-30
ATE498693T1 (de) 2011-03-15
WO2005059172A3 (en) 2005-12-08
CA2549852A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
DE602004031405D1 (de) Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
Griner et al. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
EP2527444A3 (de) Antisense-Oligonukleotid-Modulation einer STAT3-Expression
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
NZ577805A (en) Genetic markers for risk management of cardiac arrhythmia
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
WO2008134596A3 (en) Use of methylated or unmethylated line-i dna as a cancer marker
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
DE60326748D1 (de) Verfahren zur identifizierung des brustkrebsrisikos
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
MXPA05006034A (es) Proteina de duplicacion.
TW200628168A (en) Use of organic compounds
Pham et al. Expression analysis of nha-oc/NHA2: a novel gene selectively expressed in osteoclasts
DE602004032329D1 (de) Marker für präkanzeröse und kanzeröse zellen sowie verfahren zur störung der zellproliferation darin
CN106319043A (zh) 长链非编码rna linc01420的应用方法
PT1618195E (pt) Método para inibição selectiva do gene n-myc humano em tumores expressando n-myc, através de ácidos nucleicos peptídicos (pna) anti-sentido e sentido
EP2576816A4 (de) Verfahren und kit zur unterscheidung zwischen brustkrebs und einer gutartigen brusterkrankung
GB0320648D0 (en) Molecular marker
WO2006063285A3 (en) Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2009045965A3 (en) Stat5a and its functional tumor suppressor analogs for treatment of malignancies expressing npm/alk and other oncogenic kinases
DE50015171D1 (de) Rna polymerase i transkriptionsfaktor tif-ia